ReviewOncoTargets and therapy2019
Update on elotuzumab for the treatment of relapsed/refractory multiple myeloma: patients' selection and perspective.
Review in OncoTargets and therapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.
- Biological research on the occurrence and development of multiple myeloma and its treatment.Immunity, inflammation and disease · 2023Pooled it
- Good Cop, Bad Cop: Profiling the Immune Landscape in Multiple Myeloma.Biomolecules · 2023Review
- Review
- Therapeutics to harness the immune microenvironment in multiple myeloma.Cancer drug resistance (Alhambra, Calif.) · 2022Review
- Comparison of Anticancer Drug Toxicities: Paradigm Shift in Adverse Effect Profile.Life (Basel, Switzerland) · 2021Review
- Review
- Keeping Myeloma in Check: The Past, Present and Future of Immunotherapy in Multiple Myeloma.Cancers · 2021Review
- Review
- Immunotherapy of Multiple Myeloma: Promise and Challenges.ImmunoTargets and therapy · 2021Review
- The Role of Monoclonal Antibodies in the First-Line Treatment of Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma.Pharmaceuticals (Basel, Switzerland) · 2020Review
- Cardiotoxicity of Novel Targeted Hematological Therapies.Life (Basel, Switzerland) · 2020Review
- A Review of Interstitial Pneumonitis Caused by Elotuzumab Through Case Discussions and Academic Writings.Cureus · 2020Article
- The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma.Journal for immunotherapy of cancer · 2020Article
- Efficacy of ixazomib for the treatment of relapsed/refractory multiple myeloma: A protocol of systematic review and meta-analysis.Medicine · 2020Article
- The role of belantamab mafodotin for patients with relapsed and/or refractory multiple myeloma.Therapeutic advances in hematology · 2020Review
- Immunotherapy for Multiple Myeloma.Cancers · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Monoclonal antibodies (mAbs) targeting antigens expressed by plasma cells demonstrated major clinical activity in multiple myeloma patients and therefore became a new major class of drug for these patients. Elotuzumab is a humanized mAb targeting the cell surface signaling lymphocytic activation molecule family member 7, a glycoprotein highly expressed on plasma cells, that is the second mAb approved for the treatment of myeloma patients. The mechanism of action of elotuzumab includes natural killer cell (NK) mediated antibody-dependent cellular cytotoxicity and direct activation of NK-cells. Elotuzumab has been approved in combination with lenalidomide and dexamethasone (Elo-Rd) and pomalidomide and dexamethasone (Elo-Pd) for the treatment of relapsed myeloma patients. The present review will focus on elotuzumab, providing a summary of the mechanism of action, efficacy and safety and taking into consideration patients' selection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.